Plasma aldosterone in hypertensive patients on chronic hemodialysis: Distribution, determinants and impact on survival

Hypertension Research

Volumn 29, Issue 8, 2006, Pages 597-604

  Kohagura, Kentaro ^a   Higashiuesato, Yusushi ^a   Ishiki, Tetsuya ^a   Yoshi, Shinichiro ^b   Ohya, Yusuke ^a   Iseki, Kunitoshi ^a   Takishita, Shuichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Okinawa Dai ichi Hospital   (Japan)

Author keywords

Aldosterone; Cardiovascular disease; Mortality; Renal dialysis; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREDICTION; PROPORTIONAL HAZARDS MODEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

AGED; ALDOSTERONE; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENIN;

EID: 33748950282     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.597     Document Type: Article

References (27)

1. Lonn EM, Yusuf S, Jha P, et al: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
2. Givertz MM: Manipulation of the renin-angiotensin system. Circulation 2001; 104: E14-E18.
3. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
4. Pitt B, Reichek N, Willenbrock R, et al: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
5. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, CONSENSUS Trial Study Group: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
6. Rouleau JL, Packer M, Moye L: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-591.
7. Sato A, Hayashi K, Narse M, Saruta T: Effectiveness aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
8. Tozawa M, Iseki K, Iseki C, Takishita S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717-726.
9. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE: Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85: 1199-1206.
10. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
11. Park JB, Schiffrin EL Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15: 164-169.
12. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106: 2848-2853.
13. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12: 867-873.
14. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL: Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-1257.
15. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
16. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
18. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P: Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65: 1G-7G.
19. Campbell SE, Janicki JS, Matsubara BB, Weber KT: Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens 1993; 6: 487-495.
20. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-1030.
21. Wilson DR, Ing TS, Metcalfe-Gibson A, Wrong OM: The chemical composition of faeces in uraemia, as revealed by in-vivo faecal dialysis. Clin Sci 1968; 35: 197-209.
22. Oliver WJ, Cohen EL, Neel JV: Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation 1975; 52: 146-151.
23. + current in T lymphocytes. Clin Diagn Lab Immunol 2005; 12: 808-813.
24. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-24320.
25. Silvestre JS, Robert V, Heymes C, et al: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273: 4883-4891.
26. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H: Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000; 36: 495-500.
27. Kigoshi T, Uehara K, Furuya K, et al: Relationship between impaired aldosterone response to adrenocorticotropic hormone and prevalence of hemodialysis in type 2 diabetic patients without azotemia. Hypertens Res 2005; 28: 21-26.